Tuberculosis Trial, Recruiting NCT04923958 Sponsor: University of California, San Francisco Condition: Tuberculosis
Back to Tuberculosis

Tuberculosis Trial, Recruiting

NCT04923958
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the new TB testing study:

  • You are 12 years old or older and are not currently staying in a hospital
  • You have had a cough lasting 2 weeks or longer, OR you have a risk factor for TB (such as being HIV-positive, having been in close contact with someone who had TB, or having worked in a mine) AND you have tested positive on a TB screening tool
  • If you are HIV-positive, your screening result must show a specific protein level in your blood (CRP above 5 mg/dL) or an abnormal chest X-ray (confirm with trial site)
  • If you had close contact with a TB patient or worked in a mine, you must have had an abnormal chest X-ray
  • You live within 20km (about 12 miles) of the study site and are willing to come back for follow-up visits

For the drug-resistance testing study:

  • You are 12 years old or older and have already tested positive for TB and for resistance to a key TB medication (rifampicin), based on routine tests
  • You are able to provide at least two sputum (mucus) samples of at least 3mL each within one day of joining the study

For the health worker usability study:

  • You are a health worker aged 18 or older who is involved in routine TB testing at one of the study clinics

Who may not be able to join:

For the new TB testing study:

  • You finished treatment for TB (active or latent/inactive) within the last 12 months
  • You have taken any antibiotic that can affect TB bacteria — including a type called fluoroquinolones — for any reason, within the last 2 weeks
  • You live more than 20km from the study site, or you are not willing to come back for follow-up visits
  • You are not willing to sign a consent form agreeing to take part

For the drug-resistance testing study:

  • Your sputum (mucus) culture samples at the start of the study all come back negative or unusable
  • You are unable to provide at least two sputum samples of 3mL each within one day of joining
  • You are not willing or able to sign a consent form agreeing to take part

For the health worker usability study:

  • You are not willing to sign a consent form agreeing to take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Adithya Cattamanchi, MD, University of California, San Francisco

Phone: +1-415-206-5489

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 April 2021
Est. completion
31 May 2031

Where this trial is recruiting

🇬🇪 Georgia 🇮🇳 India Nigeria 🇵🇭 Philippines 🇿🇦 South Africa Uganda 🇻🇳 Vietnam Zambia

Primary endpoints

Sensitivity; Specificity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov